4
Changes in Ownership
Karyopharm Therapeutics Inc. Filed Acc 0001209191-23-010509
EVP, Chief Development Officer sold 5,869 shares at an average $3.19 ($18,717)
From the SEC's structured data for this filing
Trades in this filing
Poulton Stuart · EVP, Chief Development Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-02-15 | Sale : show line 1 in the form | −5,665 | $3.19 | $18,071 | 64,335 | D |
| 2023-02-15 | Sale : show line 2 in the form | −8 | $3.23 | $26 | 64,327 | D |
| 2023-02-15 | Sale : show line 3 in the form | −196 | $3.16 | $619 | 64,131 | D |
| Open-market sales · 5,869 sh · avg $3.19 · $18,717 | ||||||
Loading xslF345X03/doc4.xml…